{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T22:07:07Z","timestamp":1768774027168,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.amjcard.2017.11.028","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T18:24:45Z","timestamp":1513016685000},"page":"584-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A])"],"prefix":"10.1016","volume":"121","author":[{"given":"Kanjana S.","family":"Perera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesly A.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Benavente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.11.028_bib0010","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0015","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0025","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0035","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0045","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximegalatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Executive Steering Committee on behalf of the SPORTIF III Investigators","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0050","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"SPORTIF Executive Steering Committee for the SPORTIF V Investigators","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0055","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","article-title":"Causes of death in anticoagulated patients with atrial fibrillation","volume":"68","author":"Gomez-Outes","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0060","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0065","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.ahj.2005.06.026","article-title":"Rationale for design of ACTIVE: the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events","volume":"151","author":"ACTIVE Steering Committee on behalf of the ACTIVE Investigators","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0070","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0075","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1161\/STROKEAHA.114.005789","article-title":"Predictors of mortality in patients with lacunar stroke in the Secondary Prevention of Small Subcortical Strokes Trial","volume":"45","author":"Sharma","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0080","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Metanalysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0085","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0090","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0095","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/eurheartj\/ehq250","article-title":"Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE W","volume":"31","author":"De Catrina","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0100","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0105","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0140-6736(14)62052-3","article-title":"Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis","volume":"385","author":"Elmariah","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0110","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1161\/STROKEAHA.112.656173","article-title":"Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials","volume":"43","author":"Palacios","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0115","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"Benavente","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0120","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0125","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/eurheartj\/ehs348","article-title":"Increased mortality among patients taking digoxin\u2014analysis from the AFFIRM study","volume":"34","author":"Whitbeck","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0130","doi-asserted-by":"crossref","first-page":"e004006","DOI":"10.1161\/JAHA.116.004006","article-title":"Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review","volume":"5","author":"Zhu","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0135","article-title":"Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis","volume":"16","author":"Lavie","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.11.028_bib0140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/heartjnl-2015-308887","article-title":"Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation","volume":"102","author":"Hijazi","year":"2016","journal-title":"Heart"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917318532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917318532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T09:51:01Z","timestamp":1535190661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917318532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0002914917318532"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.11.028","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A])","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}